EHA 2018 | Promising outlook for frontline blinatumomab in Ph+ ALL
Giovanni Martinelli
• 14 Jun 2018
Acute lymphoblastic leukemia (ALL) is currently treated with a regimen of drugs that, while effective to an extent, could be improved upon. In this interview, Giovanni Martinelli, MD, of the Istituto Scientifico Romagnolo, Meldola, Italy, talks about a recently developed drug, blinatumomab. While the data from the current clinical trial, GIMEMA LAL2116 (NCT02744768), has only recently become available, Prof. Martinelli is hopeful for this treatment. This interview took place at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
